[Clinical research advances for small-molecule nucleic acid drugs in the treatment of chronic hepatitis B].

Currently, the commonly used antiviral drugs for hepatitis B virus (HBV) primarily include nucleos(t)ide analogues and interferons, which effectively suppress viral replication but typically have difficulty achieving clinical cure of chronic hepatitis B (CHB). Recent clinical trials have demonstrated that small-molecule nucleic acid drugs have favorable safety profiles for CHB treatment. Thus, these drugs have the potential to become a novel breakthrough point in CHB and demonstrate promising prospects in terms of clinical cure by inducing the degradation of viral RNA and activating the body's immune response to clear hepatitis B surface antigen. This review summarized the current clinical research advances for small-molecule nucleic acid drugs in the treatment of CHB.